The presently disclosed subject matter provides compositions and kits comprising light-emitting versions of the monoclonal antibody to C3d (mAB 3d29) for imaging and methods of use thereof for detecting infectious and inflammatory cells in vivo. The presently disclosed subject matter also provides methods for detecting and/or monitoring a Mycobacterium tuberculosis (M. tuberculosis) infection in a subject, as well as methods of treating a M. tuberculosis infection in a subject.

Antibodies for molecular imaging of vulnerable plaques in atherosclerosis Antibody specifically binding to atherosclerosis lesions for in vivo imaging and methods for in vivo imaging of atherosclerosis lesions in a patient.

Antibodies for molecular imaging of vulnerable plaques in atherosclerosis Antibody specifically binding to atherosclerosis lesions for in vivo imaging and methods for in vivo imaging of atherosclerosis lesions in a patient.

The present disclosure provides an isolated, engineered or non-naturally occurring protein comprising an antibody light chain variable domain (V.sub.L) which may comprise at least one negatively charged amino acid positioned between residues 49 to 56 according to the numbering system of Kabat, the protein capable of binding specifically to an antigen.

The present disclosure provides an isolated, engineered or non-naturally occurring protein comprising an antibody light chain variable domain (V.sub.L) which may comprise at least one negatively charged amino acid positioned between residues 49 to 56 according to the numbering system of Kabat, the protein capable of binding specifically to an antigen.

The present invention relates to variable domain of a camelid heavy-chain antibodies directed to amyloid β and conjugates thereof. The present invention also relates to the use of these antibody conjugates for treating or diagnosing disorders mediated by amyloid β deposits.

The present invention relates to variable domain of a camelid heavy-chain antibodies directed to amyloid β and conjugates thereof. The present invention also relates to the use of these antibody conjugates for treating or diagnosing disorders mediated by amyloid β deposits.

The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.

Embodiments in accordance with the present disclosure include antibody binding domains that specifically bind to mesothelin. A nanobody or conjugate construct thereof can comprise the antibody binding domain comprising complementary determining region (CDR)1 of SEQ ID NO:05 or SEQ ID NO:08, CDR2 of SEQ ID NO:06 or SEQ ID NO:09, and/or CDR3 of SEQ ID NO:07 or SEQ ID NO:10. The nanobody or conjugate constructs of the nanobody can be used for diagnosis or treatment of diseases or conditions associated with overexpression of mesothelin.

Embodiments in accordance with the present disclosure include antibody binding domains that specifically bind to mesothelin. A nanobody or conjugate construct thereof can comprise the antibody binding domain comprising complementary determining region (CDR)1 of SEQ ID NO:05 or SEQ ID NO:08, CDR2 of SEQ ID NO:06 or SEQ ID NO:09, and/or CDR3 of SEQ ID NO:07 or SEQ ID NO:10. The nanobody or conjugate constructs of the nanobody can be used for diagnosis or treatment of diseases or conditions associated with overexpression of mesothelin.